MetaCap

Filana Therapeutics (FLNA) vs NanoViricides (NNVC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NanoViricides (NNVC) has outperformed Filana Therapeutics (FLNA) over the past year, losing 10.2% versus a loss of 77.7%. Over five years, NNVC leads with a -76.5% price change compared with -98.9% for FLNA. Filana Therapeutics is the larger company by market cap ($32.3 million vs $29.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FLNA-77.66%NNVC-10.24%
+53%-19%-92%
Nov 21, 20251 yearNov 20, 2026
FLNA-98.79%NNVC-75.16%
+11%-47%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FLNA versus NNVC key metrics
MetricFLNANNVC
Share price$0.6413$1.14
Market cap$32.26M$29.13M
1-day change+14.52%-2.56%
YTD return-67.61%+0.88%
1-year return-77.66%-10.24%
5-year return-98.85%-76.54%
EPS (TTM)$-0.87$-0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-90.97M$-8.22M
52-week high$3.45$1.93
52-week low$0.39$0.85
Distance from 52-week high-81.41%-40.93%
Analyst consensusnonestrong_buy
Avg. price target upside+913.57%+426.32%
Average volume2.09M356.86K
Shares outstanding50.30M25.55M
Employees177
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NNVC has outperformed FLNA by 67.4 percentage points over the past year.

About Filana Therapeutics

FLNA stock →

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About NanoViricides

NNVC stock →

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

FLNA vs NNVC FAQ

Which is bigger, Filana Therapeutics or NanoViricides?

Filana Therapeutics (FLNA) is larger, with a market capitalization of $32.26M compared with $29.13M for NanoViricides (NNVC).

Which stock has performed better over the past year, FLNA or NNVC?

NNVC returned -10.24% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.

Are Filana Therapeutics and NanoViricides in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons